{"entity":{"id":"nct05199272","kind":"trial","name":"A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies","aka":[],"tldr":"A phase 1/2 trial of 23ME-00610 in renal cell carcinoma, ovarian cancer, neuroendocrine tumours and small-cell lung cancer, run by 23andMe, Inc., active and no longer recruiting.","summary":"A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT05199272 by 23andMe, Inc., with 141 participants enrolled, started 2021-12-29 and due to reach its primary completion in 2025-03. Interventions recorded: 23ME-00610.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05199272","url":"https://clinicaltrials.gov/study/NCT05199272"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc","ovarian","neuroendocrine","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct05199272-cancer-res-commun-2025"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05199272","phase":"1/2","setting":"A Phase 1/2a, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients With Advanced Solid Malignancies","sponsor":"23andMe, Inc.","participation":[{"nct":"NCT05199272","source":"https://clinicaltrials.gov/study/NCT05199272","fetchedAt":"2026-10-07T16:53:36.501Z","studySha256":"e249e553794bf298c23a024138e4aa36b37031ddfc0a2859df54635bbc88cb49","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2024-11-15","leadSponsor":"23andMe, Inc.","collaboratorCount":0,"minimumAge":"12 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":141,"enrolmentType":"ESTIMATED","siteCount":13,"recruitingSiteCount":0,"countries":["Canada","United States"]}],"started":"2021-12-29","startedType":"actual","enrolled":141,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05199272/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"paper":[{"id":"paper-nct05199272-cancer-res-commun-2025","kind":"paper","name":"First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies","route":"/key-papers/paper-nct05199272-cancer-res-commun-2025/"}]}}